Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP2 | P08253 | 4/20 | 0.52 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.50 |
| ▸ | TACR1 | P25103 | 1/20 | 0.50 |
| ▸ | SCN4A | P35499 | 2/20 | 0.45 |
| ▸ | ITGB3 | P05106 | 2/20 | 0.44 |
| ▸ | ITGA2B | P08514 | 2/20 | 0.44 |
| ▸ | ANPEP | P15144 | 1/20 | 0.44 |
| ▸ | MAOA | P21397 | 1/20 | 0.43 |
| ▸ | TLR2 | O60603 | 4/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29324444 | 0.83 | EPHX1 (0.61) | MMP2EPHX1TACR1SCN4AANPEP | |
| SCHEMBL7450428 | 0.78 | EPHX1 (0.55) | MMP2EPHX1TACR1SCN4AANPEP | |
| SCHEMBL7450422 | 0.78 | EPHX1 (0.55) | MMP2EPHX1TACR1SCN4AANPEP | |
| SCHEMBL7450433 | 0.78 | EPHX1 (0.55) | MMP2EPHX1TACR1SCN4AANPEP | |
| SCHEMBL16429484 | 0.78 | EPHX1 (0.59) | MMP2EPHX1ANPEPMAOA | |
| SCHEMBL16429100 | 0.78 | EPHX1 (0.59) | MMP2EPHX1ANPEPMAOA | |
| SCHEMBL8639910 | 0.78 | EPHX1 (0.59) | MMP2EPHX1ANPEPMAOA | |
| SCHEMBL8629574 | 0.78 | EPHX1 (0.59) | MMP2EPHX1ANPEPMAOA | |
| Hydrochloric Acid SCHEMBL28199429 | 0.76 | EPHX1 (0.57) | MMP2EPHX1ANPEPMAOA | |
| Hydrochloric Acid SCHEMBL28198880 | 0.76 | EPHX1 (0.57) | MMP2EPHX1ANPEPMAOA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7371852-B2 | Alkyl-linked nucleotide compositions | SERENEX, INC. (US) | 2008-05-13 | — | — | US | disclosed |
| US-7371852-B2 | Alkyl-linked nucleotide compositions | SERENEX, INC. (US) | 2008-05-13 | — | — | US | disclosed |
| EP-1585754-A2 | ALKYL-LINKED NUCLEOTIDE COMPOSITIONS | Serenex, Inc. (US) | 2005-10-19 | — | — | EP | disclosed |
| US-20040215009-A1 | Alkyl-linked nucleotide compositions | SERENEX, INC. (US) | 2004-10-28 | — | — | US | disclosed |
| WO-2004065566-A2 | ALKYL-LINKED NUCLEOTIDE COMPOSITIONS | SERENEX, INC. (US) | 2004-08-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040215009-A1 | Alkyl-linked nucleotide compositions | NT5C3B, NUDT1, NT5C2 | MMP2 4039/4885EPHX1 1790/4885TACR1 4216/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.